ArticleJournal of nanobiotechnology2026
Injectable pH-responsive carboxymethyl cellulose hydrogel for sustained delivery of IL-22 in the treatment of alcoholic liver disease.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Alcoholic liver disease (ALD) is a major chronic liver disorder that poses a significant global health burden due to its severe health risks and limited therapeutic options. Although recombinant interleukin-22 (IL-22) is an available therapeutic agent with potent anti-inflammatory and anti-lipid accumulation effects, its application in ALD treatment has been limited by its short half-life. In this study, we developed a carboxymethyl cellulose hydrogel (CMC)-encapsulated system to prolong the half-life of recombinant IL-22, aiming to achieve effective and sustained inhibition of ALD. Recombinant IL-22 was incorporated into CMC (IL-22@CMC) through hydrogen bonding interactions. This system exhibited pH-responsive drug delivery properties and good biocompatibility. IL-22@CMC reduced alanine aminotransferase (ALT) levels from 250 IU/L to 100 IU/L and aspartate aminotransferase (AST) levels from 700 IU/L to 200 IU/L. These levels were significantly lower than those observed with IL-22 alone (160 IU/L and 400 IU/L, respectively), indicating superior therapeutic efficacy in alcoholic liver injury. RNA sequencing analysis indicated that the enhanced inhibitory effect of IL-22@CMC was achieved through suppression of endoplasmic reticulum stress mediated by the AMP-activated protein kinase/sirtuin 1 signaling pathway in ethanol-induced AML-12 cells. By designing a pH-responsive hydrogel, this study integrates therapeutic agents with a hydrogel carrier via hydrogen bonding, thereby providing an effective strategy for developing drug delivery composites for inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.